Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00913796
Other study ID # 3200B0-112299
Secondary ID
Status Completed
Phase Phase 2
First received April 1, 2009
Last updated October 21, 2010
Start date December 2007
Est. completion date March 2010

Study information

Verified date June 2009
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

Acidosis (accumulation of acid in the body) may be an underrecognized problem in patients after renal transplantation. It may have consequences on physical performance due to negative effects on bone and muscle metabolism.

Therefore, the purpose of this study is

1. to determine the status of physical capacity and bone structure in renal transplant patients with metabolic acidosis

2. to study the effect of substituting base equivalents (citrate) on acid/base status of renal transplant patients with acidosis

3. to compare the status of physical capacity and bone structure in renal transplant patients with metabolic acidosis before and after substitution with citrate


Description:

Chronic kidney disease is developing to become one of the major health problems in the Western world with more than one million patients on renal replacement therapy, and many more expected in the years ahead [1]. Survival of patients with end stage renal disease has become possible with the introduction of dialysis therapy. Renal transplantation has resulted both in further reduction of mortality and improvement in quality of life for patients with end stage renal disease. Nevertheless, successful transplantation with regard to graft and patient survival is still associated with significant morbidity. Apart from infectious complications and cardiovascular disease, limitations in physical capacity from musculoskeletal disorders have become a relevant problem, resulting in reduced quality of life, poor physical functioning and inability to work.

Muscle and bone metabolism in chronic kidney disease are typically disturbed resulting in significant pathology and dysfunction of the affected tissues. They are associated with metabolic disorders related to renal insufficiency, among which metabolic acidosis is a major contributor. Metabolic acidosis is a well recognized problem in renal transplant patients. However, its prevalence, pathogenesis, course and sequelae are not well established. In particular, its relation to post-transplant bone and muscle disorders, and the impact on physical capabilities in renal transplant patients have not been comprehensively investigated so far.

The purpose of the proposed project is to examine the characteristics and pathogenesis of post-transplant metabolic acidosis, and its relation to bone and muscle pathologies and impact on physical capabilities in renal transplant patients. In particular, the following aims are proposed to investigate in de novo and long-term renal transplantation:

Aim # 1: To examine the type, degree and course of metabolic acidosis in renal transplant patients, early and long-term after transplantation

Aim # 2: To examine alterations in mineral and bone metabolism, and bone structure, and their relationship to the acid/base disorder

Aim # 3: To examine overall physical performance, exercise capacity and muscle energy content, and their relationship to the acid/base disorder

In order to analyze secondary effects of subclinical and overt acidosis on bone (Aim # 2) and muscle (Aim # 3), patients will be studied at baseline, and then be supplemented with base equivalents in order to achieve a stable plasma serum bicarbonate concentration of 24-26 mmol/l, and be reexamined thereafter. Completion of the three aims will allow to comprehensively analyze the pathogenesis of and interrelations between acid/base status, mineral metabolism, bone disorders and muscle function in renal transplant patients. This will be the first study to link metabolic alterations to structural and functional measures of the musculoskeletal system, and to the impact of the resulting pathologies on physical disabilities in patients with a kidney graft. We are in dire need to know the magnitude of the problem, whether to treat, and how aggressive to treat these patients. The results of this project will be indispensable regarding justification to rigorously evaluate and treat metabolic acidosis in patients with chronic renal insufficiency and after transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients with a renal graft having been transplanted within the previous 8 years and being at least 3 months post transplantation, or, patients scheduled to undergo transplantation from a living organ donor within the upcoming 3 months

- Venous serum bicarbonate concentration < 24 mmol/L at time of baseline determination

- Renal transplant function with a calculated glomerular filtration rate (GFR) greater or equal 30 ml/min according to the Cockcroft-Gault formula

- Immunosuppressive therapy including a calcineurin inhibitor (cyclosporine A or tacrolimus)

- Age 20 through 65 years of either sex

- Written informed consent for study participation

Exclusion Criteria:

- Acute rejection episode requiring specific therapy within 4 weeks before study inclusion

- Severe impairment in general health and/or physical handicaps (malignant neoplasia, catabolic state, acute systemic infection requiring therapy)

- Mental illness, psychiatric disorder

- Tetracycline intolerance

- Planned or "overt" pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Intervention

Drug:
Potassium citrate
2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
Potassium chloride
370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.

Locations

Country Name City State
Switzerland University Hospital of Zurich Zurich

Sponsors (3)

Lead Sponsor Collaborator
University of Zurich Swiss Federal Institute of Technology, University of Texas Southwestern Medical Center

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correction of metabolic acidosis 12 months No
Secondary Improvement in physical capacity 12 months No
See also
  Status Clinical Trial Phase
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Completed NCT03317444 - Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Recruiting NCT05582824 - Lactate Metabolism in the Hypoperfused Critically Ill
Active, not recruiting NCT04010630 - Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU N/A
Completed NCT02303548 - Bicarbonate in Patients With Out-of-hospital Cardiac Arrest Phase 2
Recruiting NCT01860001 - Incidence of Postoperative Ketosis and Metabolic Acidosis N/A
Completed NCT01452412 - Alkali Therapy in Chronic Kidney Disease Phase 2/Phase 3
Terminated NCT03710291 - Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis Phase 3
Completed NCT02476253 - Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill Phase 3
Completed NCT05940935 - The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations
Withdrawn NCT03846258 - High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy Phase 4
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Terminated NCT04727528 - Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Completed NCT02098356 - Comparison of High Versus Low Bicarbonate Hemodialysis N/A
Recruiting NCT03897101 - Inflammation and Metabolic Acidosis at Birth (AGAIN: AutophaGy AcIdosis Newborn)
Terminated NCT01894594 - Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease Phase 1
Completed NCT01075750 - Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants N/A
Completed NCT01295190 - Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass N/A
Completed NCT01293266 - Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation N/A